China-based Duality Biotherapeutics' (HKEX:09606) partner, Avenzo Therapeutics, Inc., a California-based clinical-stage biotechnology company developing next-generation oncology therapies, announced on Tuesday that the first patient has been dosed in the Phase 1 portion of a Phase 1/2 clinical study evaluating AVZO-1418/DB-1418.
AVZO-1418/DB-1418 is a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumours.
On January 7, 2025, DualityBio and Avenzo announced that they had entered into an exclusive license agreement, pursuant to which Avenzo will develop, manufacture, and commercialise AVZO-1418/DB-1418 globally (excluding Greater China).
The Phase 1/2 first-in-human, open-label clinical study is designed to assess the safety, tolerability, and preliminary clinical activity of AVZO-1418/DB-1418 as a single agent and in combination therapy in patients with advanced solid tumours.
REGENXBIO reports RGX-202 preclinical results in Duchenne Muscular Dystrophy
MetaVia doses first patient in 48 mg MAD cohort of DA-1726 Phase 1 trial
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies